Biocon Biologics
Sandeep Kamath has a vast experience in the pharmaceutical industry, currently holding the position of General Manager at Biocon Biologics for the Insulin business unit. Prior to this role, Kamath served as an Associate Director for the Insulin MSAT division at Biocon. With a background in microbiology and pharmaceutical business management, Kamath has held various managerial and scientific roles at companies such as USV Limited, Shantha Biotechnics Limited, and FDC Limited. Kamath also holds a post-graduate diploma in Bioinformatics from the Bioinformatics Institute of India.
This person is not in any teams
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics